Gynecological organ-preserving cystectomy (GOPC) shows similar disease-free survival rates to standard radical cystectomy, with no reported relapses in gynecological organs. Patients who undergo GOPC ...
Radical cystectomy involves bladder removal and urinary diversion, often using a laparoscopic robot-assisted approach for precision and access. The surgery lasts four to six hours, with a recovery ...
Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...
The US Food and Drug Administration (FDA) has granted approval to Inlexzo (gemcitabine intravesical system) for the treatment of certain types of bladder cancer. This decision marks a milestone for ...
Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...
Nearly 84,000 Americans will receive a bladder cancer diagnosis this year, yet most people remain unaware of the early warning signs that could save their lives. This silent disease often masquerades ...
What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback